Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR9071] to PHOX2A
- Suitable for: WB, ICC/IF
- Reacts with: Mouse, Human
Product nameAnti-PHOX2A antibody [EPR9071]
See all PHOX2A primary antibodies
DescriptionRabbit monoclonal [EPR9071] to PHOX2A
Tested applicationsSuitable for: WB, ICC/IFmore details
Unsuitable for: Flow Cyt,IHC-P or IP
Species reactivityReacts with: Mouse, Human
Synthetic peptide, coresponding to residues in Human PHOX2A (UniProt: O14813).
- SH-SY-5Y and Neuro-2a cell lysates; SH-SY-5Y cells.
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20ºC.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab155084 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 30 kDa.|
|ICC/IF||1/100 - 1/250.|
FunctionMay be involved in regulating the specificity of expression of the catecholamine biosynthetic genes. Acts as a transcription activator/factor. Could maintain the noradrenergic phenotype.
Involvement in diseaseDefects in PHOX2A are the cause of congenital fibrosis of extraocular muscles type 2 (CFEOM2) [MIM:602078]. CFEOM encompasses several different inherited strabismus syndromes characterized by congenital restrictive ophthalmoplegia affecting extraocular muscles innervated by the oculomotor and/or trochlear nerves. CFEOM is characterized clinically by anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head. CFEOM2 may result from the aberrant development of the oculomotor (nIII), trochlear (nIV) and abducens (nVI) cranial nerve nuclei.
Sequence similaritiesBelongs to the paired homeobox family.
Contains 1 homeobox DNA-binding domain.
- Information by UniProt
- Aristaless homeobox (Drosophila) fibrosis of extraocular muscles congenital 2 autosomal recessive antibody
- Aristaless homeobox gene homolog (Drosophila) antibody
- Aristaless homeobox homolog antibody
Immunofluorescent analysis of SH-SY-5Y cells, labeling PHOX2A with ab155084 at 1/100 dilution.
All lanes : Anti-PHOX2A antibody [EPR9071] (ab155084) at 1/1000 dilution
Lane 1 : SH-SY-5Y cell lysate
Lane 2 : Neuro-2a cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 30 kDa
ab155084 has not yet been referenced specifically in any publications.